• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Glycorex Transplantation

1.77 SEK

+5.99 %

Less than 1K followers

GTAB B

NGM Main Regulated

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+5.99 %
+46.28 %
+32.09 %
+11.32 %
+16.45 %
-22.71 %
-40.00 %
-82.41 %
-82.57 %

Glycorex Transplantation is active in biotechnology. The company conducts research, development and marketing in the field of organ transplantation. The company's main product enables transplants regardless of the blood type of the donor or recipient. Transplantation using the company's product is carried out on a global level. Glycorex Transplantation was founded in 1996 and has its headquarters in Lund.

Read more
Market cap
139.57M SEK
Turnover
7.13K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
28.8.
2026

Interim report Q2'26

27.11.
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release06.02.2026 klo 14.47

Glycorex Transplantation: JHLT-recognised ABO-incompatible paediatric transplant study

Glycorex Transplantation
Press release13.08.2025 klo 13.50

Glycorex Transplantation (GTAB B): First ABO-incompatible organ transplantion in Morocco with Glycosorb® ABO

Glycorex Transplantation
Press release28.02.2025 klo 10.06

Glycorex Transplantation (GTAB B): Enters distribution agreement in Greece for Glycosorb® ABO in the field of transfusion and transplantation

Glycorex Transplantation

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release18.02.2025 klo 16.26

Glycorex Transplantation AB: First ABO-incompatible transplantation in Portugal with Glycosorb® ABO

Glycorex Transplantation
Press release23.12.2024 klo 09.30

Glycorex Transplantation AB (GTAB B): First blood group-incompatible pediatric heart transplantation in Austria using Glycosorb® ABO

Glycorex Transplantation
Press release13.09.2024 klo 12.15

Glycorex Transplantation AB (GTAB B): Results from Norwegian platelet evaluation presented at conference

Glycorex Transplantation
Press release13.08.2024 klo 11.00

Glycorex Transplantation AB: First ABO-incompatible transplantation in Argentina with Glycosorb® ABO

Glycorex Transplantation
Press release13.05.2024 klo 09.20

Glycorex Transplantation: Glycosorb® ABO is pushing the boundaries in paediatric blood group incompatible heart transplantation

Glycorex Transplantation
Press release08.05.2024 klo 14.24

Glycorex Transplantation: First publication from South Africa and first stem cell transplantation performed in Mexico

Glycorex Transplantation
Press release20.02.2024 klo 13.39

Glycorex Transplantation (GTAB B): Signs agreement with distributor in Romania

Glycorex Transplantation
Regulatory press release29.11.2023 klo 11.31

Glycorex Transplantation AB: Entering into an agreement with Bio-Rad Laboratories, Inc.

Glycorex Transplantation
Regulatory press release29.11.2023 klo 09.00

Glycorex Transplantation AB (publ): Interim Report January - September 2023

Glycorex Transplantation
Regulatory press release30.08.2023 klo 09.00

Glycorex Transplantation AB (publ): Interim Report January - June 2023

Glycorex Transplantation
Regulatory press release24.05.2023 klo 09.00

Glycorex Transplantation AB (publ): Interim Report January - March 2023

Glycorex Transplantation
Regulatory press release28.04.2023 klo 19.00

Annual Report 2022 Glycorex Transplantation AB (publ)

Glycorex Transplantation
Press release09.03.2023 klo 16.00

Glycorex Transplantation: Published study from the US shows promising results on the use of Glycosorb® ABO to provide low-titer group O whole blood

Glycorex Transplantation
Regulatory press release28.02.2023 klo 09.00

Glycorex Transplantation: Year-end Report 2022

Glycorex Transplantation
Press release20.02.2023 klo 13.00

Glycorex Transplantation: The first blood group incompatible kidney transplant using Glycosorb® ABO performed in South Africa

Glycorex Transplantation
Press release31.01.2023 klo 17.00

Glycorex Transplantation: Glycorex strengthens the organization to place additional force behind the growth strategy Going 4 Growth

Glycorex Transplantation
Regulatory press release24.11.2022 klo 09.00

Glycorex Transplantation AB (GTAB B): Interim report January - September 2022

Glycorex Transplantation